PDCD1LG2 and nonpapillary renal cell carcinoma: Interestingly, we found that the key immune checkpoints PD-1, CTLA4, PD-L1 and PD-L2 all present a high level in patients with higher MYBL1 expression, indicating that MYBL1 might affect the immunotherapy response of ccRCC patients (Figures 3M–P).